{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:38Z","timestamp":1790014838241,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Current treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. Patients aged more than 12 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP, had recorded of cannabis use in medical chart, and had positive urine test of cannabis on the first day of admission from October 2013 to September 2019 were enrolled. The primary outcome was the efficacy of pharmacological treatment of CIP. Brief Psychotic Rating Scale (BPRS) on the first day and weekly after receiving treatment were used to assess the primary outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four hundred and three medical charts with diagnosis of CIP were enrolled into the study and only 317 charts were analyzed. Most of them were male with an average aged of 21.0 (19.0\u201324.0) years old. All of them used smoked cannabis from dried leaves and flowers of cannabis plant. The presented symptoms on admission were psychosis, mood symptoms, sleep problems, weight loss, and cognitive problems (100%, 64%, 61%, 11%, and 7%, respectively). Baseline BPRS score of the first day of admission was 55.2\u2009\u00b1\u20099.6. Majority of patients received antipsychotic (98.7%) followed by the combination of antipsychotics with benzodiazepines (34.5.%), antipsychotics with antidepressants (14.4%) and antipsychotics treatment with antidepressants and benzodiazepines (25.9%). Only few patients received antipsychotic monotherapy (17.9%). Risperidone was the most frequently prescribed antipsychotics (83.6%). Mean equivalence dose of risperidone was 8.0\u2009\u00b1\u20095.9\u00a0mg\/day. The average hospital length of stay was 28 days\u00a0(range 22-31). BPRS at 22 days significantly improved compared to the first day of admission (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Schizophrenia was diagnosed in 7% at 1.3 years of follow up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Antipsychotics was still a key psychotropic drug for treatment of CIP. The symptoms were decreased rapidly and sustained among the treatment period. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov ID: NCT04945031 (Registration Date: 30 June, 2021).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-06075-6","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:02:41Z","timestamp":1727434961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Onrumpha","family":"Chuenchom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanarat","family":"Suansanae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumsum","family":"Lukanapichonchut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somporn","family":"Suwanmajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuthamanee","family":"Suthisisang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"6","key":"6075_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.neuropharm.2005.11.023","volume":"50","author":"A Pisanu","year":"2006","unstructured":"Pisanu A, Acquas E, Fenu S, Di Chiara G. Modulation of Delta (9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors. Neuropharmacology. 2006;50(6):661\u201370.","journal-title":"Neuropharmacology"},{"key":"6075_CR2","first-page":"1493","volume":"2","author":"SAP Andreasson","year":"1987","unstructured":"Andreasson SAP, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longtitudinal study of Swedish conscripts. Lancet. 1987;2:1493\u20136.","journal-title":"Lancet"},{"issue":"1","key":"6075_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0b013e31820c23fa","volume":"5","author":"RD Crean","year":"2011","unstructured":"Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1\u20138.","journal-title":"J Addict Med"},{"issue":"4","key":"6075_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00213-006-0508-y","volume":"188","author":"M Ranganathan","year":"2006","unstructured":"Ranganathan M, D\u2019Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425\u201344.","journal-title":"Psychopharmacology"},{"issue":"5","key":"6075_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","volume":"6","author":"M Di Forti","year":"2019","unstructured":"Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427\u201336.","journal-title":"Lancet Psychiatry"},{"key":"6075_CR6","unstructured":"Treatment PMNIDA. Number and percent of patient 2019. http:\/\/www.pmnidat.go.th\/thai\/index.php?option=com_content&task=view&id=3274&Itemid=53. Accessed 18 Jan 2020."},{"issue":"3","key":"6075_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00004850-199905030-00005","volume":"14","author":"M Berk","year":"1999","unstructured":"Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999;14(3):177\u201380.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"6075_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/13651500009177999","volume":"4","author":"S Berk","year":"2000","unstructured":"Berk S, Brook F, Nur M. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomized controlled trial. Int J Psychiatry Clin Pract. 2000;4(2):139\u201342.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"6075_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/00005053-199211000-00007","volume":"180","author":"MMR Bell","year":"1992","unstructured":"Bell MMR, Beam-goulet J, Lysaker P, Cicchetti D. The positive and negative syndrome scale and the brief Psychiatric Rating Scale. J Nerv Ment Dis. 1992;180:723\u20138.","journal-title":"J Nerv Ment Dis"},{"key":"6075_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JEGD Overall","year":"1962","unstructured":"Overall JEGD. The brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799\u2013812.","journal-title":"Psychol Rep"},{"issue":"1","key":"6075_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s42238-022-00121-4","volume":"4","author":"SR Sommano","year":"2022","unstructured":"Sommano SR, Tangpao T, Pankasemsuk T, Ponpanumas V, Phimolsiripol Y, Rachtanapun P, et al. Growing ganja permission: a real gate-way for Thailand\u2019s promising industrial crop? J Cannabis Res. 2022;4(1):10.","journal-title":"J Cannabis Res"},{"key":"6075_CR12","first-page":"201","volume":"260","author":"DRJM Compton","year":"1992","unstructured":"Compton DRJM, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992;260:201\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"6075_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fnhum.2014.00537","volume":"8","author":"JH Hsieh","year":"2014","unstructured":"Hsieh JH, Stein DJ, Howells FM. The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci. 2014;8:537.","journal-title":"Front Hum Neurosci"},{"key":"6075_CR14","unstructured":"Gazette TR, editor. List of narcotic drug type 5. In: Health Mo, editor. Bangkok 14 December B.E. 2563 (2020) Thai government; 2020. pp. 33\u20134."},{"key":"6075_CR15","unstructured":"PMNIDAT. Number an percent of inpatients 2023. http:\/\/www.pmnidat.go.th\/thai\/index.php?option=com_content&task=view&id=4597&Itemid=53. Accessed 6 Feb 2024."},{"issue":"1\u20132","key":"6075_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.psychres.2014.08.010","volume":"220","author":"I Morales-Munoz","year":"2014","unstructured":"Morales-Munoz I, Jurado-Barba R, Ponce G, Martinez-Gras I, Jimenez-Arriero MA, Moratti S, et al. Characterizing cannabis-induced psychosis: a study with prepulse inhibition of the startle reflex. Psychiatry Res. 2014;220(1\u20132):535\u201340.","journal-title":"Psychiatry Res"},{"key":"6075_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1034\/j.1600-0447.2002.1o079.x","volume":"105","author":"LAGM Nunez","year":"2002","unstructured":"Nunez LAGM. Cannabis-induced psychosis: a cross-sectional comparison with acute schizhophrenia. Acta Psychiatr Scand. 2002;105:173\u20138.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"6075_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/bs11030037","volume":"11","author":"A Frolli","year":"2021","unstructured":"Frolli A, Ricci MC, Cavallaro A, Lombardi A, Bosco A, Di Carmine F, et al. Cognitive Development and Cannabis Use in adolescents. Behav Sci (Basel). 2021;11(3):37.","journal-title":"Behav Sci (Basel)"},{"issue":"13","key":"6075_CR19","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.2174\/13816128113199990426","volume":"20","author":"JTS Jacobus","year":"2014","unstructured":"Jacobus JTS. Effects of Cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186\u201393.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"6075_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bpsgos.2022.01.008","volume":"3","author":"B-C Ho","year":"2022","unstructured":"Ho B-C, Barry AB, Koeppel JA, Macleod J, Boyd A, David A, et al. Recreational Marijuana Use, adolescent Cognitive Development, and Schizophrenia susceptibility. Biol Psychiatry Glob Open Sci. 2022;3(2):222\u201332.","journal-title":"Biol Psychiatry Glob Open Sci"},{"issue":"3","key":"6075_CR21","doi-asserted-by":"publisher","first-page":"e009888","DOI":"10.1136\/bmjopen-2015-009888","volume":"6","author":"R Patel","year":"2016","unstructured":"Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open. 2016;6(3):e009888.","journal-title":"BMJ Open"},{"key":"6075_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neuropharm.2017.04.018","volume":"124","author":"R Mizrahi","year":"2017","unstructured":"Mizrahi R, Watts JJ, Tseng KY. Mechanisms contributing to cognitive deficits in cannabis users. Neuropharmacology. 2017;124:84\u20138.","journal-title":"Neuropharmacology"},{"key":"6075_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","volume":"162","author":"N Schooler","year":"2005","unstructured":"Schooler N, Rabinowitz J, Davidson M, Harvey PD, Kopala L, McGorry PD, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947\u201353.","journal-title":"Am J Psychiatry"},{"issue":"7629","key":"6075_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature20153","volume":"539","author":"MA Bloomfield","year":"2016","unstructured":"Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Delta (9)-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369\u201377.","journal-title":"Nature"},{"key":"6075_CR25","first-page":"100221","volume":"10","author":"E Rozin","year":"2019","unstructured":"Rozin E, Vanaharam V, D\u2019Mello D, Palazzolo S, Adams C. A retrospective study of the role of long-acting injectable antipsychotics in preventing rehospitalization in early psychosis with cannabis use. Addict Behav Rep. 2019;10:100221.","journal-title":"Addict Behav Rep"},{"key":"6075_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1192\/bjp.178.2.116","volume":"178","author":"J Andrew","year":"2001","unstructured":"Andrew J. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178:116\u201322.","journal-title":"Br J Psychiatry"},{"key":"6075_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1600-0447.1991.tb07378.x","volume":"83","author":"AGTEJ Imade","year":"1991","unstructured":"Imade AGTEJ. A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatr Scand. 1991;83:134\u20136.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"6075_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbz102","volume":"46","author":"B Murrie","year":"2020","unstructured":"Murrie B, Lappin J, Large M, Sara G. Transition of Substance-Induced, brief, and atypical psychoses to Schizophrenia: a systematic review and Meta-analysis. Schizophr Bull. 2020;46(3):505\u201316.","journal-title":"Schizophr Bull"},{"key":"6075_CR29","doi-asserted-by":"publisher","first-page":"1134130","DOI":"10.3389\/fncel.2023.1134130","volume":"17","author":"Y Paes-Colli","year":"2023","unstructured":"Paes-Colli Y, Trindade PMP, Vitorino LC, Piscitelli F, Iannotti FA, Campos RMP, et al. Activation of cannabinoid type 1 receptor (CB1) modulates oligodendroglial process branching complexity in rat hippocampal cultures stimulated by olfactory ensheathing glia-conditioned medium. Front Cell Neurosci. 2023;17:1134130.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"6075_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/YCO.0b013e3282f51266","volume":"21","author":"LE DeLisi","year":"2008","unstructured":"DeLisi LE. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry. 2008;21(2):140\u201350.","journal-title":"Curr Opin Psychiatry"},{"key":"6075_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fphar.2013.00169","volume":"4","author":"P S\u00e1nchez-Bl\u00e1zquez","year":"2014","unstructured":"S\u00e1nchez-Bl\u00e1zquez P, Rodr\u00edguez-Mu\u00f1oz M, Garz\u00f3n J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol. 2014;4:169.","journal-title":"Front Pharmacol"},{"key":"6075_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fphar.2012.00101","volume":"3","author":"A Caballero","year":"2012","unstructured":"Caballero A, Tseng KY. Association of Cannabis Use during adolescence, prefrontal CB1 receptor signaling, and Schizophrenia. Front Pharmacol. 2012;3:101.","journal-title":"Front Pharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06075-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T22:02:49Z","timestamp":1727474569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06075-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6075"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06075-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by Institutional Review Board of Faculty of Dentistry\/Faculty of Pharmacy, Mahidol University (MU-DT\/PY-IRB 2019\/074.3110; Oct 31, 2019) and the PMNIDAT, Department of Mental Health, Ministry of Public Health, Thailand (No. 010\/2563; Nov 8, 2019). Informed consent for all patients, including those\u2009<\u200918 years old, was waived by the ethics committee because of the study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"626"}}